Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV disease in infants.

Yun Ki-wook, a professor in SNUH's Department of Pediatric Infectious Diseases, discusses the domestic release of Beyfortus, an antibody treatment for respiratory syncytial virus, during a press ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 4, 2025 /EINPresswire / -- How Has the Beyfortus Market Expanded in Recent Years? The Beyfortus market has experienced significant growth, driven by ...

Driving this performance were multiple success stories, including the blockbuster respiratory syncytial virus preventative Beyfortus and Dupixent, which posted annual net sales exceeding 13 ...